Create account

Coverage dated October 24, 2026 to October 26, 2026

Amgen's cancer drug combo cut death risk by 58% in lung cancer trial

Headline from Quartz

Median survival reached 21.1 months with Imdelltra plus AstraZeneca's Imfinzi, versus 12.7 months for Imfinzi alone

Quartz's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

3 articles, oldest first.

  1. Bloomberg

    Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer (opens Bloomberg)

    Published

    Bloomberg's feed description

    Doctors combined powerful medicines from Amgen Inc. and AstraZeneca Plc and found they allowed patients with an aggressive form of lung cancer to live eight months longer.

  2. Independent Journal Review

    Amgen Reports Combo Cuts Lung Cancer Death Risk 58% (opens Independent Journal Review)

    Published

    Independent Journal Review's feed description

    A Phase 3 trial found that adding Amgen’s Imdelltra to AstraZeneca’s Imfinzi as maintenance therapy for extensive-stage small cell lung cancer reduced the risk of death by 58%, with median survival of 21.1 months versus 12.7 months on Imfinzi alone.

  3. Quartz

    Amgen's cancer drug combo cut death risk by 58% in lung cancer trial (opens Quartz)

    Published

    Quartz's feed description

    Median survival reached 21.1 months with Imdelltra plus AstraZeneca's Imfinzi, versus 12.7 months for Imfinzi alone

Amgen's cancer drug combo cut death risk by 58% in lung cancer trial | Since Then